The Committee for Medicinal Products for Human Use (CHMP) issued positive opinions regarding the drug’s application for adults and adolescents. Rinvoq, already cleared for several other autoimmune conditions, is currently a primary revenue driver for the North Chicago-based firm. AbbVie projects that total sales for the drug will exceed $10 billion throughout the current year.

While the European Commission typically aligns with CHMP recommendations, a final regulatory decision is expected in the coming months. For patients, the approval would mark a significant shift in managing non-segmental vitiligo, which often manifests as persistent, symmetrical white skin patches, and severe alopecia areata, characterized by varied patterns of hair loss.